BIAF · bioAffinity Technologies, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current expected level of operating expenditures, current expected levels of revenue, and the cash and cash equivalents on hand at June 30, 2026, of $2.4 million, management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements contained in this Quarterly Report.”View the 10-Q filed Aug 7, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $5.9M | $6.16M | $9.36M | $7.9MG | $6.9M | — | |
| — | — | — | — | $467 | — | |
| — | — | — | — | $4336 | — | |
| — | — | — | — | 0.06% | — | |
| $1.42M | $1.38M | $1.46M | $1.47M | $1.38M | $1.01M | |
| $11.35M | $9.91M | $9.94M | $6.79M | $2.48M | $1.07M | |
| $58.34K | $58.33K | $58.33K | $16.53K | $0 | — | |
| $413.09K | $504.84K | $605.64K | $249.59K | $10.18K | $4817 | |
| $18.28M | $16.73M | $18.32M | $10.51M | $4.02M | $2.21M | |
| -$12.38M | -$10.57M | -$8.95M | -$7.97M | -$4.01M | -$2.21M | |
| — | -171.58% | -95.64% | -100.93% | -58.13% | — | |
| -$11.97M | -$10.07M | -$8.35M | -$7.72M | -$4M | -$2.2M | |
| $44.84K | $44.37K | $92.48K | $37.13K | $2.53M | $1M | |
| $34.2K | $23.39K | $17.61K | $122.13K | $46.71K | $424 | |
| -$2.8M | -$4.29M | -$74.74K | $57.21K | -$4.14M | — | |
| -$15.18M | -$14.87M | -$9.03M | -$7.92M | -$8.15M | -$6.32M | |
| — | $44.04K | $11.65K | $20.99K | $2459 | $1950 | |
| -$15.19M | -$14.91M | -$9.04M | -$7.94M | -$8.15M | -$6.33M | |
| — | -241.96% | -96.56% | -100.47% | -118.18% | — | |
| USD/shares | -$3.60 | -$129.90 | -$337.50 | -$409.50 | -$814.50 | -$1,062.00 |
| USD/shares | -$3.60 | -$129.90 | -$337.50 | -$409.50 | -$814.50 | — |
| shares | — | 114.74K | 26.94K | 19.44K | 9997.6978 | 5945.0444 |
| shares | — | 114.74K | 26.94K | 19.44K | 9997.6978 | — |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of notes payable | 2026-06-30 | USD 22,561 | 10-Q filed 2026-08-07 |
| Finance lease liabilities | 2026-06-30 | USD 575,060 | 10-Q filed 2026-08-07 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Noncurrent notes payable | 2026-06-30 | USD 36,465 | 10-Q filed 2026-08-07 |
| Operating lease liabilities | 2026-06-30 | USD 800,919 | 10-Q filed 2026-08-07 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Laboratory Services | $6,161,382 | $9,353,368 | $2,513,057 | $4,803 |
| Health Care Patient Service | $4,971,342 | $8,175,670 | $2,199,558 | — |
| Histology Service Fees | $1,116,912 | $1,103,751 | $272,660 | — |
| Medical Director Fees | $68,268 | $66,576 | $19,324 | — |
| Other Revenues | $4,860 | $7,371 | $21,515 | — |
| Department of Defense Observational Studies | $577 | $8,654 | $19,442 | — |
| Diagnostic Research and Development | $577 | $8,654 | $19,442 | — |
| Department of Defense Observational Studiesr | — | — | $19,442 | — |
| Histology Fees | — | — | $272,660 | — |
| Health Care Other | — | — | $19,324 | — |